Welcome to our dedicated page for Nu Skin Enter news (Ticker: NUS), a resource for investors and traders seeking the latest updates and insights on Nu Skin Enter stock.
Nu Skin Enterprises, Inc. reports developments tied to its beauty and wellness business, affiliate opportunity platform and international market operations. Company updates commonly cover quarterly revenue and earnings, customer, paid affiliate and sales leader trends, dividend declarations, cost discipline and product commercialization across Nu Skin personal care, Pharmanex nutrition and ageLOC anti-aging brands.
Recurring news also includes the rollout of Prysm iO, an intelligent wellness platform that uses skin scans to provide antioxidant-related insights, and activity at Rhyz, the company’s strategic investment arm for consumer, technology and manufacturing businesses in beauty, wellness and lifestyle categories. Leadership appointments and operating-structure changes are also part of the company’s public updates.
Nu Skin Enterprises (NYSE:NUS) reported 2Q26 revenue of $320.1M, adjusted net income of $10.0M and adjusted EPS of $0.20, matching Stonegate Capital Partners’ EPS estimate but below its revenue estimate of $345.2M. GAAP EPS was ($5.14), mainly due to a $78.9M non-cash goodwill impairment and a $167.5M deferred-tax valuation allowance, both excluded from adjusted results.
Core Nu Skin gross margin rose 20 bps year over year to 77.7%, while consolidated gross margin fell 60 bps to 68.2% and adjusted operating margin declined 190 bps to 6.1%. Nu Skin and Rhyz revenue fell 15.5% and 25.0% year over year, respectively. Management reduced FY26 revenue guidance to $1.28B–$1.35B from $1.35B–$1.50B and adjusted EPS guidance to $0.70–$0.90 from $0.80–$1.20, and shifted the India market timing to 1H27. The Prysm iO platform remains the key growth initiative, with over 39,000 devices placed, 2.5M scans completed, and a year-end target of 50,000–60,000 devices, alongside early signs of sales-leader stabilization.
Nu Skin Enterprises (NYSE: NUS) reported Q2 2026 revenue of $320.1 million, down 17.1% year over year with a 1.0% negative FX impact. Reported EPS was $(5.14), or $0.20 on an adjusted basis excluding non-cash impairment and tax charges, compared with $0.43 a year ago. Customers fell 14% to 660,037, Paid Affiliates declined 8% to 120,291, and Sales Leaders decreased 9% to 26,998.
Gross margin was 68.2% (Nu Skin business 77.7%). Operating margin was (18.5)%, or 6.1% excluding a non-cash impairment charge. According to the company, Q3 2026 revenue is expected between $310–$340 million with adjusted EPS of $0.10–$0.20, and full-year 2026 revenue of $1.28–$1.35 billion with adjusted EPS of $0.70–$0.90.
Nu Skin Enterprises (NYSE: NUS) announced that its board of directors has declared a quarterly cash dividend of $0.06 per share. The dividend is scheduled to be paid on September 9, 2026, to shareholders of record as of August 28, 2026.
Nu Skin Enterprises (NYSE: NUS) will release its second quarter 2026 financial results after the market close on Monday, Aug. 10. Management will host a conference call with investors the same day at 5 p.m. ET to discuss recent results and upcoming business initiatives.
The live webcast, including financial information, will be accessible via the investor relations section of ir.nuskin.com, with a replay available at the same location through Monday, Aug. 24.
Nu Skin (NYSE:NUS) announced its Nourish the Children initiative has provided 900 million meals to malnourished children since 2002. The program currently feeds about 75,000 children daily across more than 65 countries through VitaMeal donations purchased by sales leaders, customers and employees.
Nu Skin (NYSE: NUS) reported Q1 2026 revenue of $320.6 million (down 12% year-over-year; +1.1% FX or $3.9 million). GAAP EPS was $0.04 ($0.14 excluding certain charges). Customers totaled 669,535 (down 14%); paid affiliates 120,850 (down 8%).
Management highlighted Prysm iO™ rollout ahead of a full consumer launch in H2 2026 and an anticipated formal launch in India in late 2026. Q2 revenue guidance is $330–360M; 2026 revenue guide is $1.35–1.50B. The company returned $8M to shareholders via dividends and buybacks and refinanced debt to extend liquidity.
Nu Skin Enterprises (NYSE: NUS) declared a quarterly cash dividend of $0.06 per share. The dividend will be paid on June 10, 2026 to shareholders of record as of May 29, 2026. This action reflects the board's approved cash distribution to shareholders.
Nu Skin (NYSE: NUS) will release first quarter 2026 results after market close on Thursday, May 7, 2026. Management will host a conference call the same day at 5:00 p.m. ET to discuss results and upcoming business initiatives.
The live webcast and financial materials will be available at ir.nuskin.com, with a replay accessible through Thursday, May 21, 2026.
Nu Skin (NYSE: NUS) launched Prysm iO, an AI-powered, fingertip skin scanner that measures carotenoid antioxidant levels in 15 seconds and is available in the U.S. for $375. The device uses patent-pending Spectral Rai Technology and a database of >20 million scans.
Clinical validation (97 participants) showed strong correlation with blood serum (R² = 0.75–0.77); Prysm iO provides a Nutrition Health Score and integrates with Nu Skin supplements.
Nu Skin Enterprises (NYSE: NUS) appointed Chelsea Lantz as interim Chief Financial Officer, effective March 20, 2026, after James Thomas stepped down to pursue an outside opportunity. The board has started a formal search for a permanent CFO while Lantz will continue cost-improvement and operational performance efforts.
Lantz joined Nu Skin in 2011, served as corporate controller since 2023, and led initiatives that the company says produced a significant year-over-year increase in EPS. She previously worked at PricewaterhouseCoopers and holds a Master of Accounting from Utah State University.